Home » Newsletters » BioWorld Science

BioWorld Science

July 27, 2018

View Archived Issues

Phase II results of JAK1/2 inhibitor baricitinib for the treatment of systemic lupus erythematosus

Use of autologous adipose-derived regenerative cells for the treatment of severe thermal burns

Novel small molecule targeting STAT5/6 reverses allergic airway disease in mice

Kinase inhibitors for familial Parkinson's may work in sporadic disease

Positive topline results presented for phase IIb study of RTB-101

PTBP1 identified as a SASP regulator that does not affect the senescence growth arrest

CFDA approves INDs for Innovent's IBI-101 and IBI-307

Researchers develop CD41-KO murine model of immune thrombocytopenia

DSMB recommends early termination of phase III study of Neutrolin owing to efficacy

New phase III trial explores subcutaneous fixed-dose combination of pertuzumab and trastuzumab

Otonomy initiates additional phase III trial of Otividex for Meniere's disease

Phase III studies of KX2-391 in actinic keratosis achieve primary endpoint

DTX-401 begins phase I/II study for glycogen storage disease type Ia

Phase I study of BTK inhibitor PRN-2246 confirms CNS exposure and promising tolerability

Medivir reports promising topline joint structure outcomes from phase IIa extension study of MIV-711

Chronic treatment with BBB-penetrable EPO analogue shows protective effects in AD mice model

Proclara advances NPT-189 for systemic amyloidosis and NPT-088 for Alzheimer's

First data presented from phase I/II study of dolutegravir dispersible tablet pediatric formulation

Continued virologic suppression in subjects with resistance mutation switching to E/C/F/TAF

Data presented for the 48-week viral suppression across age categories in the LIVING study

Viamet Pharmaceuticals describes cytochrome P450 11B2 inhibitors

Meiji Seika Pharma identifies phosphodiesterase PDE4 inhibitors

Minoryx Therapeutics patents beta-1 galactosidase mutant chaperones

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 9, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...